As of June 21, 2025, Nymox Pharmaceutical Corp (NYMX) reports a Gross Margin of N/A.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Nymox Pharmaceutical Corp's Gross Margin
Over recent years, Nymox Pharmaceutical Corp's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2022-12-31 | - |
| 2021-12-31 | - |
| 2020-12-31 | 50.00% |
| 2019-12-31 | 53.33% |
| 2018-12-31 | 31.82% |
This gradual decrease highlights how Nymox Pharmaceutical Corp manages its operational efficiency and pricing power over time.
Comparing Nymox Pharmaceutical Corp's Gross Margin to Peers
To better understand Nymox Pharmaceutical Corp's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Nymox Pharmaceutical Corp (NYMX) | - |
| Obseva SA (OBSV) | 7775.20% |
| Biomx Inc (PHGE) | 7775.20% |
| Zymeworks Inc (ZYME) | 7775.20% |
| Fusion Pharmaceuticals Inc (FUSN) | 7775.20% |
| Aptinyx Inc (APTX) | 7775.20% |
Compared to its competitors, Nymox Pharmaceutical Corp's Gross Margin is difficult to compare due to insufficient data.